BeiGene (BGNE) Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary Distress Did Not Meet Co-primary Efficacy Endpoints

Go back to BeiGene (BGNE) Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary Distress Did Not Meet Co-primary Efficacy Endpoints
(NASDAQ: BGNE) Delayed: 305.40 -4.85 (1.56%)
Previous Close $310.25    52 Week High $36.76 
Open $308.71    52 Week Low $22.51 
Day High $318.58    P/E N/A 
Day Low $305.00    EPS $0.00 
Volume 129,165